Inhibition of the purinergic P2X7 receptor improves renal perfusion in angiotensin-II-infused rats

Kidney International

Volumn 88, Issue 5, 2015, Pages 1079-1087

  Menzies, Robert I ^a,b   Howarth, Amelia R ^a   Unwin, Robert J ^c,d   Tam, Frederick W K ^e   Mullins, John J ^a   Bailey, Matthew A ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

ATP; Blood oxygenation level dependent magnetic resonance imaging; Kidney disease; Kidney injury; Purinergic

Indexed keywords

ANGIOTENSIN II; AZ 11657312; PURINERGIC P2X7 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; SODIUM; UNCLASSIFIED DRUG; URINARY TRACT AGENT; MESSENGER RNA; NITRIC OXIDE; OXYGEN; PURINERGIC P2X RECEPTOR ANTAGONIST; VASOCONSTRICTOR AGENT;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG MEGADOSE; FISCHER 344 RAT; GENETIC SUSCEPTIBILITY; HYPERTENSION; HYPOXIA; IN VIVO STUDY; KIDNEY CORTEX; KIDNEY FIBROSIS; KIDNEY INJURY; KIDNEY MEDULLA; KIDNEY PERFUSION; MALE; MICROANGIOPATHY; NATRIURESIS; NONHUMAN; P2RX7 GENE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RENOVASCULAR DISEASE; SHIFT TO THE LEFT; SODIUM EXCRETION; TISSUE OXYGENATION; ANIMAL; BLOOD; BLOOD PRESSURE; DRUG EFFECTS; GENE EXPRESSION; GENETICS; KIDNEY CIRCULATION; METABOLISM; PHYSIOLOGY; VASCULAR ENDOTHELIUM; VASCULARIZATION; VASOCONSTRICTION;

ANGIOTENSIN II; ANIMALS; BLOOD PRESSURE; ENDOTHELIUM, VASCULAR; GENE EXPRESSION; KIDNEY CORTEX; KIDNEY MEDULLA; MALE; NATRIURESIS; NITRIC OXIDE; OXYGEN; PURINERGIC P2X RECEPTOR ANTAGONISTS; RATS; RATS, INBRED F344; RECEPTORS, PURINERGIC P2X7; RENAL CIRCULATION; RNA, MESSENGER; VASOCONSTRICTION; VASOCONSTRICTOR AGENTS;

EID: 84947618061     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2015.182     Document Type: Article

References (53)

1. Jha V, Garcia-Garcia G, Iseki K et al. Chronic kidney disease: global dimension and perspectives. Lancet 2013; 382: 260-272.
2. Eckardt KU, Coresh J, Devuyst O et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet 2013; 382: 158-169.
3. Eckardt KU, Bernhardt WM, Weidemann A et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl 2005; 99: S46-S51.
4. Fine LG, Norman JT. Chronic hypoxia as a mechanism of progression of chronic kidney diseases: from hypothesis to novel therapeutics. Kidney Int 2008; 74: 867-872.
5. Cachofeiro V, Goicochea M, de Vinuesa SG et al. Oxidative stress and inflammation, a link between chronic kidney disease and cardiovascular disease. Kidney Int Suppl 2008; 111: S4-S9.
6. Oberg BP, McMenamin E, Lucas FL et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int 2004; 65: 1009-1016.
7. Drawz PE, Sedor JR. The genetics of common kidney disease: a pathway toward clinical relevance. Nat Rev Nephrol 2011; 7: 458-468.
8. Schulz A, Kreutz R. Mapping genetic determinants of kidney damage in rat models. Hypertens Res 2012; 35: 675-694.
9. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344: 541-544.
10. Mullins LJ, Bailey MA, Mullins JJ. Hypertension, kidney, and transgenics: a fresh perspective. Physiol Rev 2006; 86: 709-746.
11. Kantachuvesiri S, Fleming S, Peters J et al. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Biol Chem 2001; 276: 36727-36733.
12. Ashek A, Menzies RI, Mullins LJ et al. Activation of thiazide-sensitive co-transport by angiotensin II in the cyp1a1-Ren2 hypertensive rat. PLoS One 2012; 7: e36311.
13. Kantachuvesiri S, Haley CS, Fleming S et al. Genetic mapping of modifier loci affecting malignant hypertension in TGRmRen2 rats. Kidney Int 1999; 56: 414-420.
14. Liu X, Bellamy CO, Bailey MA et al. Angiotensin-converting enzyme is a modifier of hypertensive end organ damage. J Biol Chem 2009; 284: 15564-15572.
15. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010; 31: 541-550.
16. Menzies RI, Unwin RJ, Dash RK et al. Effect of P2X4 and P2X7 receptor antagonism on the pressure diuresis relationship in rats. Front Physiol 2013; 4: 305.
17. Burnstock G, Evans LC, Bailey MA. Purinergic signalling in the kidney in health and disease. Purinergic Signal 2014; 10: 71-101.
18. Mariathasan S, Weiss DS, Newton K et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-232.
19. Ferrari D, Pizzirani C, Adinolfi E et al. The P2X7 receptor: a key player in IL-1 processing and release. J Immunol 2006; 176: 3877-3883.
20. Turner CM, Tam FW, Lai PC et al. Increased expression of the proapoptotic ATP-sensitive P2X7 receptor in experimental and human glomerulonephritis. Nephrol Dial Transplant 2007; 22: 386-395.
21. Taylor SR, Turner CM, Elliott JI et al. P2X7 deficiency attenuates renal injury in experimental glomerulonephritis. J Am Soc Nephrol 2009; 20: 1275-1281.
22. Ji X, Naito Y, Weng H et al. P2X7 deficiency attenuates hypertension and renal injury in deoxycorticosterone acetate-salt hypertension. Am J Physiol Renal Physiol 2012; 303: F1207-F1215.
23. Ray FR, Huang W, Slater M et al. Purinergic receptor distribution in endothelial cells in blood vessels: a basis for selection of coronary artery grafts. Atherosclerosis 2002; 162: 55-61.
24. Yamamoto K, Korenaga R, Kamiya A et al. P2X(4) receptors mediate ATP-induced calcium influx in human vascular endothelial cells. Am J Physiol Heart Circ Physiol 2000; 279: H285-H292.
25. Menzies RI, Unwin RJ, Bailey MA. Renal P2 receptors and hypertension. Acta Physiol (Oxf) 2015; 213: 232-241.
26. Crawford C, Kennedy-Lydon TM, Callaghan H et al. Extracellular nucleotides affect pericyte-mediated regulation of rat in situ vasa recta diameter. Acta Physiol (Oxf) 2011; 202: 241-251.
27. Nishiyama A, Majid DS, Taher KA et al. Relation between renal interstitial ATP concentrations and autoregulation-mediated changes in renal vascular resistance. Circ Res 2000; 86: 656-662.
28. Graciano ML, Nishiyama A, Jackson K et al. Purinergic receptors contribute to early mesangial cell transformation and renal vessel hypertrophy during angiotensin II-induced hypertension. Am J Physiol Renal Physiol 2008; 294: F161-F169.
29. Brezis M, Rosen S. Hypoxia of the renal medulla-its implications for disease. N Engl J Med 1995; 332: 647-655.
30. Mattson DL. Importance of the renal medullary circulation in the control of sodium excretion and blood pressure. Am J Physiol Regul Integr Comp Physiol 2003; 284: R13-R27.
31. Wang CT, Chin SY, Navar LG. Impairment of pressure-natriuresis and renal autoregulation in ANG II-infused hypertensive rats. Am J Physiol Renal Physiol 2000; 279: F319-F325.
32. Jiang LH, Mackenzie AB, North RA et al. Brilliant Blue G selectively Blocks ATP-gated rat P2X(7) receptors. Mol Pharmacol 2000; 58: 82-88.
33. Cruwys S, Midha A, Rendall E et al. Antagonism of the P2X7 receptor attenuates joint destruction in a model of arthritis. Am Coll Rheumatol Abstr 2007: 1772.
34. Menzies RI, Zammit-Mangion A, Hollis LM et al. An anatomically unbiased approach for analysis of renal BOLD magnetic resonance images. Am J Physiol Renal Physiol 2013; 305: F845-F852.
35. Ji X, Naito Y, Hirokawa G et al. P2X(7) receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. Hypertens Res 2012; 35: 173-179.
36. Vonend O, Turner CM, Chan CM et al. Glomerular expression of the ATPsensitive P2X receptor in diabetic and hypertensive rat models. Kidney Int 2004; 66: 157-166.
37. Lister MF, Sharkey J, Sawatzky DA et al. The role of the purinergic P2X7 receptor in inflammation. J Inflamm (Lond) 2007; 4: 5.
38. Goncalves RG, Gabrich L, Rosario A Jr et al. The role of purinergic P2X7 receptors in the inflammation and fibrosis of unilateral ureteral obstruction in mice. Kidney Int 2006; 70: 1599-1606.
39. Arulkumaran N, Unwin RJ, Tam FW. A potential therapeutic role for P2X7 receptor (P2X7R) antagonists in the treatment of inflammatory diseases. Expert Opin Investig Drugs 2011; 20: 897-915.
40. Ivy JR, Bailey MA. Pressure natriuresis and the renal control of arterial blood pressure. J Physiol 2014; 592: 3955-3967.
41. Katrahalli U, Kalanur SS, Seetharamappa J. Interaction of bioactive Coomassie Brilliant Blue G with protein: insights from spectroscopic methods. Sci Pharm 2010; 78: 869-880.
42. Ramirez AN, Kunze DL. P2X purinergic receptor channel expression and function in bovine aortic endothelium. Am J Physiol Heart Circ Physiol 2002; 282: H2106-H2116.
43. Oliveira SD, Coutinho-Silva R, Silva CL. Endothelial P2X7 receptors' expression is reduced by schistosomiasis. Purinergic Signal 2013; 9: 81-89.
44. Yamamoto K, Korenaga R, Kamiya A et al. Fluid shear stress activates Ca(2+) influx into human endothelial cells via P2X4 purinoceptors. Circ Res 2000; 87: 385-391.
45. Kanno K, Hirata Y, Imai T et al. Regulation of inducible nitric oxide synthase gene by interleukin-1 beta in rat vascular endothelial cells. Am J Physiol 1994; 267: H2318-H2324.
46. Franco M, Bautista R, Tapia E et al. Contribution of renal purinergic receptors to renal vasoconstriction in angiotensin II-induced hypertensive rats. Am J Physiol Renal Physiol 2011; 300: F1301-F1309.
47. Lewis CJ, Evans RJ. P2X receptor immunoreactivity in different arteries from the femoral, pulmonary, cerebral, coronary and renal circulations. J Vasc Res 2001; 38: 332-340.
48. Franco M, Tapia E, Bautista R et al. Impaired pressure natriuresis resulting in salt-sensitive hypertension is caused by tubulointerstitial immune cell infiltration in the kidney. Am J Physiol Renal Physiol 2013; 304: F982-F990.
49. Hewinson J, Mackenzie AB. P2X(7) receptor-mediated reactive oxygen and nitrogen species formation: from receptor to generators. Biochem Soc Trans 2007; 35: 1168-1170.
50. O'Connor PM, Cowley AW Jr. Modulation of pressure-natriuresis by renal medullary reactive oxygen species and nitric oxide. Curr Hypertens Rep 2010; 12: 86-92.
51. Inscho EW. ATP, P2 receptors and the renal microcirculation. Purinergic Signal 2009; 5: 447-460.
52. Johnson RJ, Rodriguez-Iturbe B, Kang DH et al. A unifying pathway for essential hypertension. Am J Hypertens 2005; 18: 431-440.
53. Brass D, Grably MR, Bronstein-Sitton N et al. Using antibodies against P2Y and P2X receptors in purinergic signaling research. Purinergic Signal 2012; 8: 61-79.